TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01411852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Sodium Chloride 250 mL bolus
Description: Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium Chloride 2000 mL bolus
Description: Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
Study: NCT03786380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin 10 μg
Description: Relamorelin 10 μg injected subcutaneously twice daily.
Study: NCT05643391

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioembolization using Holmium-166
Description: This technic consists of the intra-arterial infusion of smaller beads that are loaded with a radioactive isotope (yttrium-90), and it relies on the beta radiation emitted by the isotope to induce tumor necrosis, with a minor contribution from microembolization and without risk of ischemia of the remaining liver.
Study: NCT00572845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weaning of Antispasticity Medication
Description: Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
Study: NCT01328938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCPGC 3.6mg
Description: Stage I:Single blinded

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCPGC 6mg
Description: Stage I: Single blinded;
Study: NCT04514510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.~Isoquercetin given at 1000 mg, once daily by mouth for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days.
Study: NCT04571788

Intervention type: PROCEDURE
Intervention: Foldable Capsular Buckle
Description: Intraoperatively, the location and size of the fissure hole is located under the microscope to determine the location and extent of the conjunctival incision. Once local infiltration anesthesia is complete, a 2 ml needle is inserted into the outer surface of the sclera \>10 mm behind the corneoscleral rim, and a cotton swab is used to apply light pressure on the side of the wound to help drain the fluid. Under the microscope, the emptied and folded FCB was inserted vertically into the external scleral channel and the drainage valve was sutured with 5.0 non-absorbable sutures 8-10 mm behind the angular scleral rim. The balloon was then filled with 1 ml of alkaline Ringer's solution using a 1 ml syringe through the drainage valve. Subconjunctival injection of tobramycin and dexamethasone was followed by gentle pressure and bandaging of the eye.

Intervention type: PROCEDURE
Intervention: Silicone scleral padding
Description: Intraoperatively, the location and size of the fissure is located under the microscope to determine the location and extent of the incision of the bulbar conjunctiva. When the fissure hole is located microscopically, a retrobulbar block anesthesia is performed and fluid is released according to the degree of retinal detachment. Silicone was then implanted on the scleral surface as an external cushion and intraocular pressure was applied, and the opening was finally sutured, with laser closure performed within a week after surgery. After the surgery, subconjunctival injection of tobramycin and dexamethasone was routinely performed, and the operated eye was bandaged, with observation of the fundus and closure of the aperture.
Study: NCT00990795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
Study: NCT02503852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puregraft System
Description: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puregraft System
Description: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Puregraft System
Description: The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
Study: NCT01328938

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta (pegfilgrastim) 6mg
Description: Stage II: Active comparator, double blinded

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCPGC 6mg
Description: Experimental: Stage II
Study: NCT03460678

Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects

Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects
Study: NCT02291978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2100
Description: The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
Study: NCT02614638

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One month of department-wide observation
Description: A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharm Tech participates in department
Description: Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
Study: NCT01172873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: 50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: 50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and Response Prevention (EX/RP)
Description: Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and Response Prevention (EX/RP)
Description: Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
Study: NCT01711112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Treatment will be continued until progression, unacceptable toxicity, or refusal
Study: NCT01268163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: European Taxotere®
Description: 60-100 mg/m\^2 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: American Taxotere®
Description: 60-100 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hospira Docetaxel Injection
Description: 60-100 mg/m\^2 IV
Study: NCT01670370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-GemOx
Description: Rituximab Gemcitabine Oxaliplatin
Study: NCT02039258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC
Description: Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC
Description: Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
Study: NCT04144192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 1.8%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 1.8%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Study: NCT03776448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sativa Nigra oil Softgels
Description: Nigella sativa, a flowering plant native to southwest Asia, is considered one of the most important healing medicinal plants in Islamic culture. The use of its richly colored black seeds has been recommended in the prophetic medicine. It's also known by various other names amongst different cultures. Importantly, its seed is known in Arabic as 'habat al Baraka' which translates literally to 'the seed of blessing'.The active ingredient is believed to be thymoquinone richly present in the oil extract of its seeds. Apart from mild occasional gastrointestinal disturbance, black seed oil has no side effects and is considered very safe. .

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Activated Charcoal Softgels
Description: This supplement is manufactured by \[Arkopharma Pharmaceutical Laboratories\] and is available commercially. The use of activated charcoal softgels as a placebo is documented in several other clinical trials. The single most relevant characteristic of charcoal is its minimal if any gastrointestinal absorption. As a result, it does not undergo any metabolism and is excreted completely in feces. This makes charcoal an attractive placebo choice for small trials or when manufacturing a specific placebo is not feasible. Charcoal softgels are black in color and resemble black seed oil softgels to a great extent.
Study: NCT02756702

Intervention type: DEVICE
Intervention: All-Poly
Description: Implantation of the VEGA PS using all-polyethylene tibia components
Study: NCT04873089

Intervention type: OTHER
Intervention: Cosmetic product
Description: It is a comparative study with two parallel groups of subjects:~* Tested group: twice daily application of the cream RV3278A cosmetic product on the whole face~* Comparative group: no application of study product or reference product
Study: NCT01768663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: tablet, 200mg taken every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: tablet, 200mg taken every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: tablet, 200mg taken every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: tablet, 200mg taken every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: tablet, 250mg taken every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: tablet, 250mg taken every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: tablet, 250mg taken every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: tablet, 250mg taken every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 750 mg taken every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200mg taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600mg taken once daily
Study: NCT03312816

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cookies enriched with POP
Description: Cookies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cookies enriched with POP
Description: Cookies
Study: NCT02503852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution System
Description: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution System
Description: The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kerastem Therapy
Description: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kerastem Therapy
Description: The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liposuction
Description: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Liposuction
Description: Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
Study: NCT00110877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/rtv
Description: One 400mg LPV tablet twice daily with 100mg RTV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114/rtv
Description: Two 300mg TMC114 tablets twice daily with 100mg RTV
Study: NCT00488475

Intervention type: DRUG
Intervention: etanercept
Description: The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study: NCT02752698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro Hand S robotic surgery
Description: 20-70 patients undergo Micro Hand S robotic surgeries

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic surgery
Description: 20-70 patients undergo laparoscopic surgeries

Intervention type: PROCEDURE
Group type: OTHER
Intervention: da Vinci robotic surgery
Description: 20-70 patients undergo da Vinci robotic surgeries
Study: NCT01133782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access to diagnostic test
Description: Randomization to receive a result of diagostic procedure the following day.
Study: NCT04695184

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ICG-NIRF Imaging
Description: intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
Study: NCT01867333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM
Description: A recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM
Description: A recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: An androgen receptor inhibitor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: An androgen receptor inhibitor.
Study: NCT03390582

Intervention type: DRUG
Intervention: Methimazole Pill
Description: Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
Study: NCT04253873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib mesylate (0-14 days, 500 mg, qd), taken half an hour after a meal (the daily dose should be as much as possible), one week apart, and then given temozolomide (150mg/m2 for 5 Days); every 28 days is a cycle, medication to disease progression, intolerable toxicity, etc.
Study: NCT03803124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: 1 tablet before renography

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet before renography
Study: NCT04242043

Intervention type: DIAGNOSTIC_TEST
Intervention: intel@med-feasibility
Description: Initial evaluation by the Nurse using the AI tool which enters into MEDVIR the patient's symptoms or functional complaints and comorbidities and is complemented by a telemedicine solution for data transmission to the remote tele-expert physician located in a regulatory center or health center. The remote doctor (a geriatrician from Prevention Care for Elderly Unit (UPSAV) platform of the Clinical Gerontology Division of the Limoges University Hospital) analyses the data collected by the Nurse and establishes a symptom severity criterion and a diagnosis with the help of the AI technology.~Both the geriatrician and the NHs nurse are not aware of the proposals made by AI.~The geriatrician can nevertheless initiate a visit to the resident's place of residence in order to verify the information necessary to establish the diagnosis and thus improve the relevance of the algorithm. For the resident, this study doesn't interfere with the usual care.
Study: NCT01416389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously as a one hour infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ixabepilone
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Administered intravenously
Study: NCT04853641

Intervention type: PROCEDURE
Intervention: Cadaveric
Description: Cadaveric Organ Transplant

Intervention type: PROCEDURE
Intervention: Living Donor
Description: Living Donor Organ Transplant
Study: NCT04629573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumber Epidural
Description: Epidural procedure was performed by attending anesthesiologists who had completed at least 50 epidural procedures during their training. Patient was placed in the sitting position, the skin over the lumbar area was cleaned and a sterile technique was observed throughout the procedure. Skin and subcutaneous tissue were infiltrated with 1% lidocaine 2 mL at the intended site of epidural placement (L2-3 or L3-4 interspace). The lumbar epidural space was then located, using a midline approach with an 18 gauge Tuohy epidural needle via a loss of resistance technique with 2 mL of saline, 20 gauge epidural catheter was placed in each patient. We deliver an initial bolus of 20 ml bupivacaine 0.5% plus 100 mcg Fentanyl, followed by continuous infusion of bupivacaine 0.5% plus 1mcg/ml Fentanyl (3-5 ml/hr.).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Anesthesia was initiated with IV fentanyl 1 µg/kg, propofol 2 mg/kg and cisatracurium 0.15 mg/kg to facilitate endotracheal intubation. After tracheal intubation, anesthesia was maintained with sevoflurane in O2 and air (FiO2 of 0.5), cisatracurium 1µg/kg/min and fentanyl 0.5 µg/ kg /h were infused. Volume-Controlled ventilation was performed in all patients. Cisatracurium and fentanyl infusion was stopped at the end of surgery, neuromuscular blockade was reversed, and the patient was extubated and send to post-anesthesia care unit.
Study: NCT03659864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diesel exhaust particulate
Description: aerosolised diesel exhaust particulate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbon nanoparticles
Description: aerosolised 'clean' carbon nanoparticles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: small graphene oxide
Description: aerosolised 'small' graphene oxide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasmall graphene oxide
Description: aerosolised 'ultrasmall' graphene oxide

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: filtered air
Description: control: filtered air